Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label switch study of plant-cell–expressed recombinant human glucocerebrosidase (prGCD) in Gaucher disease patients treated with imiglucerase
2008-005825-12Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Mar 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of taliglucerase alfa in Gaucher disease (GD), sponsored by Protalix BioTherapeutics. Primary endpoint: Safety of prGCD. Started Mar 2009; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on 2008-005825-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005825-12.